Company registration number 13897742 (England and Wales)
HARKLINIKKEN UK LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
HARKLINIKKEN UK LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 7
HARKLINIKKEN UK LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Current assets
Stocks
4,793
-
Debtors
4
668,324
565,106
Cash at bank and in hand
71,441
38,619
744,558
603,725
Creditors: amounts falling due within one year
5
(1,758,652)
(1,556,344)
Net current liabilities
(1,014,094)
(952,619)
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
(1,014,095)
(952,620)
Total equity
(1,014,094)
(952,619)

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 27 August 2025 and are signed on its behalf by:
Mr Kasper Markussen
Director
Company registration number 13897742 (England and Wales)
HARKLINIKKEN UK LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 March 2023
1
(798,338)
(798,337)
Period ended 31 December 2023:
Loss and total comprehensive income
-
(154,282)
(154,282)
Balance at 31 December 2023
1
(952,620)
(952,619)
Year ended 31 December 2024:
Loss and total comprehensive income
-
(61,475)
(61,475)
Balance at 31 December 2024
1
(1,014,095)
(1,014,094)
HARKLINIKKEN UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
1
Accounting policies
Company information

Harklinikken UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is 46-54 High Street, Ingatestone, Essex, CM9 4DW.

1.1
Reporting period

The reporting period for the annual financial statements was for one year (2023: Ten months ending 31st December 2023) this change to the reporting period, was due to matching the year-ends of the group. Due to this, the comparative amounts presented in the financial statements (including the related notes) are not entirely comparable.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. T he company has therefore taken advantage of e xemptions from the following disclosure requirements:

- Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;

- Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issues: Interest income/expense and net gains/losses for financial instruments not measured at fair value; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;

- Section 26 ‘Share based Payment’: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;

- Section 33 ‘Related Party Disclosures’: Compensation for key management personnel.

The financial statements of the company are consolidated in the financial statements of Hairclinic Group ApS. These consolidated financial statements are available from its registered office, Amaliegade 42, St. 1256 Kobenhavn K.

1.3
Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.true

The company continues to be supported by its fellow Group and Parent companies, of which will enable the company to meet its liabilities as they fall due for at least 12 months from the date of approval of these financial statements.

Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

HARKLINIKKEN UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
1.4
Turnover

Turnover is recognised as a management charge from companies within the group to cover the costs for non-clinic personnel, who are supporting the global market.

Also the company sold hair products within the United Kingdom via it's website, revenue is recognised and invoices are raised when the products have been posted out to the customer.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

HARKLINIKKEN UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.11
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

HARKLINIKKEN UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
13
10
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Amounts owed by group undertakings and undertakings in which the company has a participating interest
626,744
461,844
Other debtors
41,580
103,262
668,324
565,106
5
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
373
-
0
Amounts owed to group undertakings
1,575,393
1,450,000
Taxation and social security
-
0
34,594
Other creditors
182,886
71,750
1,758,652
1,556,344
6
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its loss for the year then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Senior Statutory Auditor:
Neil A. Chambers
Statutory Auditor:
Taylor Viney & Marlow Limited
Date of audit report:
19 September 2025
HARKLINIKKEN UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
7
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
30,000
-
8
Events after the reporting date

The company began to reduce operations in the UK, post year-end. This included reducing staff levels and activating the break clause in the lease for April 2025.

9
Parent company

The company is a subsidiary undertaking of Hairclinic Group ApS. The ultimate parent company is EMKL Holding ApS.

2024-12-31 2024-01-01 false false false 19 September 2025 CCH Software CCH Accounts Production 2025.200 No description of principal activity Mr Kasper Markussen Mr Paul Rakkar Mr Stuart Millar 13897742 2024-01-01 2024-12-31 13897742 2024-12-31 13897742 2023-12-31 13897742 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 13897742 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 13897742 core:CurrentFinancialInstruments 2024-12-31 13897742 core:CurrentFinancialInstruments 2023-12-31 13897742 core:ShareCapital 2024-12-31 13897742 core:ShareCapital 2023-12-31 13897742 core:RetainedEarningsAccumulatedLosses 2024-12-31 13897742 core:RetainedEarningsAccumulatedLosses 2023-12-31 13897742 core:ShareCapital 2023-02-28 13897742 core:RetainedEarningsAccumulatedLosses 2023-02-28 13897742 bus:Director1 2024-01-01 2024-12-31 13897742 core:RetainedEarningsAccumulatedLosses 2023-03-01 2023-12-31 13897742 2023-03-01 2023-12-31 13897742 core:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 13897742 core:WithinOneYear 2024-12-31 13897742 core:WithinOneYear 2023-12-31 13897742 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13897742 bus:FRS102 2024-01-01 2024-12-31 13897742 bus:Audited 2024-01-01 2024-12-31 13897742 bus:Director2 2024-01-01 2024-12-31 13897742 bus:Director3 2024-01-01 2024-12-31 13897742 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13897742 bus:FullAccounts 2024-01-01 2024-12-31 xbrli:pure xbrli:shares iso4217:GBP